{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:12:10Z","timestamp":1788347530079,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40261-019-00867-5","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T16:24:33Z","timestamp":1571415873000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Collagenase Clostridium Histolyticum: A Review in Peyronie\u2019s Disease"],"prefix":"10.1007","volume":"40","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"867_CR1","unstructured":"American Urological Association. Peyronie\u2019s disease: AUA guideline; 2015. http:\/\/www.auanet.org\/guidelines\/peyronies-disease-guideline . Accessed 26 July 2019."},{"issue":"5","key":"867_CR2","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.5489\/cuaj.5255","volume":"12","author":"AJ Bella","year":"2018","unstructured":"Bella AJ, Lee JC, Grober ED, et al. 2018 Canadian Urological Association guideline for Peyronie\u2019s disease and congenital penile curvature. Can Urol Assoc J. 2018;12(5):E197\u2013209.","journal-title":"Can Urol Assoc J"},{"key":"867_CR3","unstructured":"European Medicines Agency. Xiapex (collagenase clostridium histolyticum): EU assessment report; 2014. http:\/\/www.ema.europa.eu\/ . Accessed 15 July 2019."},{"issue":"4","key":"867_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.esxm.2018.07.003","volume":"6","author":"EJ Margolin","year":"2018","unstructured":"Margolin EJ, Pagano MJ, Aisen CM, et al. Beyond curvature: prevalence and characteristics of penile volume-loss deformities in men with Peyronie\u2019s disease. Sex Med. 2018;6(4):309\u201315.","journal-title":"Sex Med"},{"issue":"6","key":"867_CR5","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie\u2019s disease. J Urol. 2006;175(6):2115\u20138.","journal-title":"J Urol"},{"key":"867_CR6","unstructured":"Hatzimouratidis K, Giuliano F, Moncada I, et al. EAU guidelines on penile curvature; 2017. http:\/\/uroweb.org\/guideline\/penile-curvature\/ . Accessed 26 July 2019."},{"key":"867_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-319-17202-6_6","volume-title":"Peyronie\u2019s disease: a comprehensive guide","author":"G Paulis","year":"2015","unstructured":"Paulis G. Natural history of Peyronie\u2019s disease. In: Cavallini G, Paulis G, editors. Peyronie\u2019s disease: a comprehensive guide. Cham: Springer; 2015. p. 27\u201337."},{"issue":"4","key":"867_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1756287218755020","volume":"10","author":"DJ Cwikla","year":"2018","unstructured":"Cwikla DJ, Yafi FA. Intralesional collagenase clostridium histolyticum in the management of Peyronie\u2019s disease: current best practice. Ther Adv Urol. 2018;10(4):139\u201353.","journal-title":"Ther Adv Urol"},{"key":"867_CR9","unstructured":"Swedish Orphan Biovitrum AB. Xiapex (collagenase clostridium histolyticum) 0.9\u00a0mg powder and solvent for solution for injection: EU summary of product characteristics; 2017. http:\/\/www.ema.europa.eu\/ . Accessed 6 June 2019."},{"key":"867_CR10","unstructured":"Endo Pharmaceuticals Inc. XIAFLEX\u00ae (collagenase clostridium histolyticum) for injection, for intralesional use: US prescribing information; 2016. http:\/\/www.fda.gov\/ . Accessed 6 June 2019."},{"key":"867_CR11","unstructured":"Endo Ventures Ltd. XIAFLEX\u00ae (collagenase clostridium histolyticum) lyophilized powder for solution 0.9\u00a0mg\/vial: Canadian product monograph; 2019. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-product-database.html . Accessed 30 July 2019."},{"issue":"12","key":"867_CR12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40265-015-0441-7","volume":"75","author":"S Dhillon","year":"2015","unstructured":"Dhillon S. Collagenase clostridium histolyticum: a review in Peyronie\u2019s disease. Drugs. 2015;75(12):1405\u201312.","journal-title":"Drugs."},{"issue":"8","key":"867_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40267-016-0318-1","volume":"32","author":"S Dhillon","year":"2016","unstructured":"Dhillon S. Collagenase clostridium histolyticum in Peyronie\u2019s disease: a guide to its use in the EU. Drugs Ther Perspect. 2016;32(8):311\u20136.","journal-title":"Drugs Ther Perspect"},{"issue":"1","key":"867_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199\u2013207.","journal-title":"J Urol."},{"key":"867_CR15","unstructured":"Data on file, Endo Pharmaceuticals Inc.; 2013."},{"issue":"2","key":"867_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","volume":"190","author":"WJ Hellstrom","year":"2013","unstructured":"Hellstrom WJ, Feldman R, Rosen RC, et al. Bother and distress associated with Peyronie\u2019s disease: validation of the Peyronie\u2019s disease questionnaire. J Urol. 2013;190(2):627\u201334.","journal-title":"J Urol"},{"issue":"4","key":"867_CR17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"LI Lipshultz","year":"2015","unstructured":"Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116(4):650\u20136.","journal-title":"BJU Int"},{"key":"867_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41443-018-0027-5","volume":"31","author":"J Kaminetsky","year":"2018","unstructured":"Kaminetsky J, Gittelman M, Kaufman GJ, et al. Patient perspectives on Peyronie\u2019s disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum. Int J Impot Res. 2018;31:263\u20138.","journal-title":"Int J Impot Res"},{"issue":"4","key":"867_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/0092623X.2011.582431","volume":"37","author":"M Yule","year":"2011","unstructured":"Yule M, Davison J, Brotto L. The International Index of Erectile Function: a methodological critique and suggestions for improvement. J Sex Marital Ther. 2011;37(4):255\u201369.","journal-title":"J Sex Marital Ther"},{"issue":"2","key":"867_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.urology.2015.04.047","volume":"86","author":"WJ Hellstrom","year":"2015","unstructured":"Hellstrom WJ, Feldman RA, Coyne KS, et al. Self-report and clinical response to Peyronie\u2019s disease treatment: Peyronie\u2019s disease questionnaire results from 2 large double-blind, randomized, placebo-controlled phase 3 studies. Urology. 2015;86(2):291\u20138.","journal-title":"Urology"},{"issue":"1","key":"867_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/jsm.12721","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Larsen SM. Surgical correction of persistent Peyronie\u2019s disease following collagenase clostridium histolyticum treatment. J Sex Med. 2015;12(1):259\u201364.","journal-title":"J Sex Med"},{"issue":"6","key":"867_CR22","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","volume":"187","author":"M Gelbard","year":"2012","unstructured":"Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268\u201374.","journal-title":"J Urol"},{"issue":"1","key":"867_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jsm.12731","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248\u201358.","journal-title":"J Sex Med"},{"issue":"2","key":"867_CR24","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.esxm.2017.02.001","volume":"5","author":"I Goldstein","year":"2017","unstructured":"Goldstein I, Knoll LD, Lipshultz LI, et al. Changes in the effects of Peyronie\u2019s disease after treatment with collagenase clostridium histolyticum: male patients and their female partners. Sex Med. 2017;5(2):e124\u201330.","journal-title":"Sex Med"},{"issue":"4 Suppl 1","key":"867_CR25","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.jsxm.2019.01.121","volume":"16","author":"I Goldstein","year":"2019","unstructured":"Goldstein I. Long-term safety and curvature deformity characterization in patients previously treated with collagenase clostridium histolyticum for Peyronie\u2019s disease [abstract no. 111]. J Sex Med. 2019;16(4 Suppl 1):S57.","journal-title":"J Sex Med"},{"issue":"4 Suppl","key":"867_CR26","first-page":"e1053","volume":"199","author":"I Goldstein","year":"2018","unstructured":"Goldstein I, Liu G, McLane M, et al. Impact of collagenase clostridium histolyticum treatment of men with Peyronie\u2019s disease on improvement of female partner sexual function [abstract no. PD54-05]. J Urol. 2018;199(4 Suppl):e1053.","journal-title":"J Urol."},{"issue":"4 Part 1","key":"867_CR27","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","volume":"195","author":"MJ Ziegelmann","year":"2016","unstructured":"Ziegelmann MJ, Viers BR, McAlvany KL, et al. Restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for Peyronie\u2019s disease. J Urol. 2016;195(4 Part 1):1051\u20136.","journal-title":"J Urol"},{"issue":"4","key":"867_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/JU.0000000000000032","volume":"201","author":"WJG Hellstrom","year":"2019","unstructured":"Hellstrom WJG, Tue Nguyen HM, Alzweri L, et al. Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with Peyronie\u2019s disease: results of a multi-institutional analysis. J Urol. 2019;201(4):777\u201382.","journal-title":"J Urol"},{"issue":"10","key":"867_CR29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","volume":"14","author":"HMT Nguyen","year":"2017","unstructured":"Nguyen HMT, Anaissie J, DeLay KJ, et al. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute-phase Peyronie\u2019s disease. J Sex Med. 2017;14(10):1220\u20135.","journal-title":"J Sex Med"},{"key":"867_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","volume":"119","author":"K Wymer","year":"2018","unstructured":"Wymer K, Ziegelmann M, Savage J, et al. Plaque calcification: an important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie\u2019s disease. Urology. 2018;119:109\u201314.","journal-title":"Urology"},{"key":"867_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urology.2017.08.037","volume":"110","author":"K DeLay","year":"2017","unstructured":"DeLay K, Diao L, Nguyen HMT, et al. Successful treatment of residual curvature in Peyronie disease in men previously treated with intralesional collagenase clostridium histolyticum. Urology. 2017;110:110\u20133.","journal-title":"Urology"},{"issue":"5","key":"867_CR32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/bju.13120","volume":"116","author":"CC Carson 3rd","year":"2015","unstructured":"Carson CC 3rd, Sadeghi-Nejad H, Tursi JP, et al. Analysis of the clinical safety of intralesional injection of collagenase clostridium histolyticum (CCH) for adults with Peyronie\u2019s disease (PD). BJU Int. 2015;116(5):815\u201322.","journal-title":"BJU Int"},{"issue":"4 Suppl","key":"867_CR33","first-page":"e882","volume":"199","author":"A Sun","year":"2018","unstructured":"Sun A, Li S, Eisenberg M. Corporal rupture and collagenase clostridium histolyticum: a population based study [abstract no. PD44-05]. J Urol. 2018;199(4 Suppl):e882\u20133.","journal-title":"J Urol"},{"issue":"4","key":"867_CR34","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jsxm.2016.02.105","volume":"13","author":"FA Yafi","year":"2016","unstructured":"Yafi FA, Anaissie J, Zurawin J, et al. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie\u2019s disease. J Sex Med. 2016;13(4):684\u20139.","journal-title":"J Sex Med"},{"issue":"4","key":"867_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2164\/jandrol.108.006221","volume":"30","author":"WJ Hellstrom","year":"2009","unstructured":"Hellstrom WJ. Medical management of Peyronie\u2019s disease. J Androl. 2009;30(4):397\u2013405.","journal-title":"J Androl"},{"issue":"4","key":"867_CR36","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/jsm.12838","volume":"12","author":"KS Coyne","year":"2015","unstructured":"Coyne KS, Currie BM, Thompson CL, et al. Responsiveness of the Peyronie\u2019s Disease Questionnaire (PDQ). J Sex Med. 2015;12(4):1072\u20139.","journal-title":"J Sex Med"},{"issue":"16","key":"867_CR37","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s40265-016-0649-1","volume":"76","author":"J Anaissie","year":"2016","unstructured":"Anaissie J, Hellstrom WJ, Yafi FA. Collagenase clostridium histolyticum for the treatment of Peyronie\u2019s disease: a \u2018real world\u2019 clinical perspective. Drugs. 2016;76(16):1523\u20138.","journal-title":"Drugs"},{"issue":"1","key":"867_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41443-018-0063-1","volume":"31","author":"PN Tsambarlis","year":"2019","unstructured":"Tsambarlis PN, Yong R, Levine LA. Limited success with collagenase clostridium histolyticum following FDA approval for the treatment of Peyronie\u2019s disease. Int J Impot Res. 2019;31(1):15\u20139.","journal-title":"Int J Impot Res"},{"issue":"1","key":"867_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41443-018-0086-7","volume":"31","author":"R Tal","year":"2019","unstructured":"Tal R. Editorial comment on \u2018Limited success with collagenase clostridium histolyticum following FDA approval for the treatment of Peyronie\u2019s disease\u2019. Int J Impot Res. 2019;31(1):54\u20135.","journal-title":"Int J Impot Res"},{"key":"867_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-019-0127-x","author":"T Masterson","year":"2019","unstructured":"Masterson T, Patel P, Ramasamy R. RE: Limited success with collagenase clostridium histolyticum following FDA approval for the treatment of Peyronie\u2019s disease. Int J Impot Res. 2019. https:\/\/doi.org\/10.1038\/s41443-019-0127-x .","journal-title":"Int J Impot Res"},{"issue":"9","key":"867_CR41","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jsxm.2019.06.010","volume":"16","author":"K Wymer","year":"2019","unstructured":"Wymer K, Kohler T, Trost L. Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in men with Peyronie\u2019s disease in an era of effective clinical treatment. J Sex Med. 2019;16(9):1421\u201332.","journal-title":"J Sex Med"},{"issue":"2","key":"867_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.urpr.2016.04.005","volume":"4","author":"BH Cordon","year":"2017","unstructured":"Cordon BH, Hofer MD, Hutchinson RC, et al. Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie\u2019s disease deformities. Urol Pract. 2017;4(2):118\u201325.","journal-title":"Urol Pract"},{"issue":"5","key":"867_CR43","doi-asserted-by":"publisher","first-page":"894","DOI":"10.21037\/tau.2017.07.27","volume":"6","author":"L Diao","year":"2017","unstructured":"Diao L, Anaissie J, Nguyen HMT, et al. Effect of collagenase clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie\u2019s disease. Transl Androl Urol. 2017;6(5):894\u20138.","journal-title":"Transl Androl Urol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00867-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00867-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00867-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T21:23:09Z","timestamp":1695331389000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00867-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00867-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,18]]},"assertion":[{"value":"18 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sheridan Hoy is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}